"The TV and print ads make false or misleading claims regarding the superiority of Crestor, " Christine Smith, a regulatory review officer at DDMAC wrote in the letter.
FORBES: FDA Warns AstraZeneca On Crestor Marketing
2.
In a letter sent to AstraZeneca, an officer at DDMAC noted that the efficacy of Crestor's top 40-milligram dose was similar to that of 80 milligrams of Lipitor in the study referenced by AstraZeneca.
FORBES: FDA Warns AstraZeneca On Crestor Marketing